Introduction:
Guillain–Barré syndrome (GBS) is an immune-related disorder with an
estimated annual incidence of 1-2 cases per 100,000 worldwide. It is the
most common cause of acute non-trauma related paralysis in the developed
world1. It manifests as acute, rapidly progressing
polyradiculoneuropathy due to inflammation and demyelination of the
peripheral nervous system, resulting in a classically symmetrical and
ascending weakness, often in association with hyporeflexia or
areflexia2. The exact cause of Guillain–Barre
syndrome is still unknown, but the suggested pathophysiology is
molecular mimicry following respiratory and gastrointestinal infections.
After the first case was reported in Wuhan, China in December 2019, the
global pandemic caused by SARS-CoV-2 brought many challenges including
the manufacturing and administration of vaccine. Several vaccines were
approved by FDA and reported side effects ranged from pain at the site
of injection, myalgia, fatigue, and fever to more serious ones including
anaphylaxis3,4. GBS was linked with some vaccines
namely, rabies, hepatitis A and B, polio and
influenza5. However, a causative relationship was not
established.